Showing results (21-30 of 109) with videos related to

Sort By:
Pageof 11
Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomesVera C Rutten, Jan-Jaap Mellema, Tahlita Cm Zuiverloon, et al.
European Urology Oncology|June 7, 2024
Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder CancerFélix Guerrero-Ramos, Joost L Boormans, Siamak Daneshmand, et al.
Plos One|December 15, 2018
Ex vivo assays to predict enhanced chemosensitization by hyperthermia in urothelial cancer of the bladderNathalie van den Tempel, Kishan A T Naipal, Anja Raams, et al.
Urologic Oncology|September 2, 2021
Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancerOlga M Pijpers, Kees Hendricksen, Hugh Mostafid, et al.
European Urology Oncology|September 11, 2022
A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association GuidelinesJoep J de Jong, Olga M Pijpers, Kim E M van Kessel, et al.
Brachytherapy|July 2, 2016
Fractionated high-dose-rate brachytherapy as monotherapy in prostate cancer: Does implant displacement and its correction influence acute and late toxicity?Shafak Aluwini, Wendy M H Busser, Lizette E A Baartman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2009
Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancerKarin G Hermans, Joost L Boormans, Delila Gasi, et al.
International Urology and Nephrology|August 23, 2022
Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching studyNoor van Ginkel, Tom J N Hermans, Dennie Meijer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 19, 2011
Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practiceGeert J L H van Leenders, Joost L Boormans, Cornelis J Vissers, et al.
European Urology|November 5, 2017
Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines PanelJoost L Boormans, Javier Mayor de Castro, Lorenzo Marconi, et al.
Pageof 11